Search results for "METASTASIS"

showing 10 items of 986 documents

Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-RE…

2013

Purpose To evaluate the efficacy of craniospinal irradiation (CSI) in the management of recurrent infant medulloblastoma after surgery and chemotherapy alone. Methods and Materials Seventeen pediatric medulloblastoma patients registered in the HIT-REZ 1997 and 2005 studies underwent CSI as salvage treatment at first recurrence. All patients had achieved complete remission after first-line treatment consisting of surgery and chemotherapy. Eleven patients showed metastatic disease at relapse. Five patients underwent surgery prior to radiation therapy, which resulted in complete resection in 1 case. In 1 patient, complete resection of the residual tumor was performed after CSI. Eleven patients…

MaleCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMedizinDisease-Free SurvivalCraniospinal IrradiationCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansRadiology Nuclear Medicine and imagingNeoplasm MetastasisChildNeoplasm StagingProportional Hazards ModelsSalvage TherapyMedulloblastomaChemotherapyUnivariate analysisRadiationBrain Neoplasmsbusiness.industryProportional hazards modelInfantRadiotherapy Dosagemedicine.disease3. Good healthSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisMultivariate AnalysisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessCraniospinal030217 neurology & neurosurgeryProgressive diseaseFollow-Up StudiesMedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-…

2004

Abstract Based on the results of combined data from three North American Phase II studies, a randomised Phase II study in the same patient population was performed, using combination chemotherapy with estramustine phosphate (EMP) and vinblastine (VBL) in hormone refractory prostate cancer patients. In all, 92 patients were randomised into a Phase II study of oral EMP (10 mg kg day continuously) or oral EMP in combination with intravenous VBL (4 mg m(2) week for 6 weeks, followed by 2 weeks rest). The end points were toxicity and PSA response in both groups, with the option to continue the trial as a Phase III study with time to progression and survival as end points, if sufficient responses…

MaleCancer Researchmedicine.medical_specialtyUrologyAdministration OralPhases of clinical researchVinblastineMetastasisClinicalProstate cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousSurvival analysishormone-escaped prostate cancerEMP/VBL vs EMPbusiness.industryProstatic NeoplasmsCombination chemotherapyProstate-Specific Antigenmedicine.diseaseSurvival AnalysisPhase IISurgeryVinblastineProstate-specific antigenOncologyDrug Resistance NeoplasmDisease ProgressionEstramustineEstramustinebusinessmedicine.drug
researchProduct

The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.

2018

BACKGROUND We examined the expression of CD200, a ligand of immune tolerance, in transitional cell carcinoma of the human bladder (TCC). MATERIALS AND METHODS CD200 was analyzed by immunohistochemistry (IHC) in 90 patients with suspected TCC lesions of the bladder. Expression of CD200 was exemplarily validated by quantitative reverse transcription polymerase chain reaction and western blot analysis. RESULTS CD200 was detectable at mRNA and protein levels in TCC homogenate and TCC cell lines (T24, UMUC3). TCC tissues showed significantly higher CD200 expression (p<0.005) than normal bladder tissues. CD200 signals were also higher in metastasized compared to localized TCC (p<0.05). CD200 was …

MaleCancer Researchmedicine.medical_treatmenturologic and male genital diseasesMetastasis03 medical and health sciences0302 clinical medicineWestern blotAntigens CDmedicineBiomarkers TumorHumansRNA MessengerRNA NeoplasmNeoplasm MetastasisneoplasmsAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellBladder cancermedicine.diagnostic_testbusiness.industryCell DifferentiationGeneral MedicineImmunotherapymedicine.diseasefemale genital diseases and pregnancy complicationsImmune checkpointNeoplasm ProteinsReverse transcription polymerase chain reactionTransitional cell carcinomaOncologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisCancer researchImmunohistochemistryFemaleTumor EscapeNeoplasm Gradingbusiness030215 immunologyAnticancer research
researchProduct

The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

MaleCancer Treatmentlcsh:MedicineGastroenterologyMetastasisGeographical LocationsMathematical and Statistical Techniques0302 clinical medicineMedicine and Health SciencesEthnicitiesLiver DiseasesLiver NeoplasmsGeneral MedicinePrognosisItalian PeopleCancer treatmentOncology030220 oncology & carcinogenesisHepatocellular carcinomaPhysical SciencesFemale030211 gastroenterology & hepatologyalpha-FetoproteinsRadiologyLiver cancerStatistics (Mathematics)Research Articlemedicine.medical_specialtyCarcinoma HepatocellularAsiaSurgical and Invasive Medical ProceduresGastroenterology and HepatologyResearch and Analysis MethodsCarcinomasChild healthDigestive System Procedures03 medical and health sciencesDiagnostic MedicineInternal medicineGastrointestinal TumorsmedicineCarcinomaHumansStatistical MethodsStaging systemNeoplasm StagingTransplantationbusiness.industrylcsh:RCancers and NeoplasmsHepatocellular CarcinomaOrgan Transplantationmedicine.diseaseLiver TransplantationPeople and PlacesPopulation GroupingsNeoplasm stagingbusinessMathematicsForecastingPLoS Medicine
researchProduct

Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery.

2021

Obesity is a strong risk factor for cancer progression, posing obesity-related cancer as one of the leading causes of death. Nevertheless, the molecular mechanisms that endow cancer cells with metastatic properties in patients affected by obesity remain unexplored. Here, we show that IL-6 and HGF, secreted by tumor neighboring visceral adipose stromal cells (V-ASCs), expand the metastatic colorectal (CR) cancer cell compartment (CD44v6 + ), which in turn secretes neurotrophins such as NGF and NT-3, and recruits adipose stem cells within tumor mass. Visceral adipose-derived factors promote vasculogenesis and the onset of metastatic dissemination by activation of STAT3, which inhibits miR-200…

MaleCancer microenvironmentobesityStromal cellColorectal cancerScienceSettore MED/50 - Scienze Tecniche Mediche ApplicateGeneral Physics and AstronomyAdipose tissueMice SCIDSCIDmetastasis.General Biochemistry Genetics and Molecular BiologyArticleMiceVasculogenesisSettore MED/04 - PATOLOGIA GENERALEmedicineAnimalsHumansNeoplasm MetastasisStem Cell NicheZinc Finger E-box Binding Homeobox 2Tumor microenvironmentMultidisciplinarybusiness.industryHepatocyte Growth FactorInterleukin-6Stem CellsQadipose stromal cellCancerCD44v6General Chemistrymedicine.diseaseCellular ReprogrammingColorectal cancerMicroRNAsAdipose TissueCancer cellColonic NeoplasmsCancer researchNeoplastic Stem Cellsconsensus molecular subtypeStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratoriobusinessNature communications
researchProduct

Molecular Pathways Involved in Prostate Carcinogenesis: Insights from Public Microarray Datasets

2012

PLoS one 7(11), e49831 (2012). doi:10.1371/journal.pone.0049831

MaleEXPRESSIONMicroarrayMicroarraysPopulationlcsh:MedicineBiologyMETABOLISMMalignancyBioinformaticsMetastasisMolecular GeneticsProstate cancerGeneticsCancer GeneticsBiomarkers TumormedicineHumansEpithelial–mesenchymal transitioneducationProstate carcinogenesislcsh:ScienceBiologyCANCER CELLSSIGNATURESOligonucleotide Array Sequence Analysiseducation.field_of_studyMultidisciplinarySystems BiologyProstate CancerCHOLESTEROLlcsh:RComputational BiologyCancers and NeoplasmsProstatic NeoplasmsGenomicsmedicine.diseaseEPITHELIAL-MESENCHYMAL TRANSITIONGene Expression Regulation NeoplasticMODELGenitourinary Tract TumorsCell Transformation NeoplasticOncologyCancer cellBIOLOGICAL PATHWAYSMedicinelcsh:QMetabolic Networks and PathwaysResearch Article
researchProduct

Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction.

2007

OBJECTIVES To determine whether matrix metalloproteinase (MMP)-9 activation resulting from prostate cancer cell-bone interaction is dependent on the tumor cell type and/or the nature of the bone microenvironment. METHODS In vitro co-cultures of human prostate cancer cells (PC3 and C4-2B) and mouse, human fetal, or human adult tissues were performed. In vivo the tumor cells were intratibially injected in SCID mice or intraosseously inoculated into fetal or adult bone xenografts in SCID mice. MMP-2 and MMP-9 expression and activation were determined by gelatin zymography in conditioned media obtained in vitro and in lysates derived from the in vivo studies at different time points. RESULTS Ac…

MaleFetusPathologymedicine.medical_specialtybusiness.industryUrologyBone metastasisProstatic NeoplasmsMice SCIDMatrix metalloproteinaseBone tissuemedicine.diseaseIn vitroBone and BonesProstate cancerMicemedicine.anatomical_structureMatrix Metalloproteinase 9In vivoCancer cellMedicineAnimalsHumansbusinessCells CulturedUrology
researchProduct

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

Pattern of occult nodal relapse diagnosed with 18F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only rad…

2014

Abstract Introduction The purpose of this study was to describe the pattern of nodal relapse with 18 F-fluoro-choline (FCH) Positron Emission Tomography/Computerized Tomography (PET/CT) in prostate cancer patients after radiotherapy. Materials and methods Eighty-three patients had a FCH PET/CT at time of biochemical failure. Of 65 patients with positive findings, 33 had positive nodes. This analysis included 31 patients who had undergone prior prostate-only radiotherapy with or without a prior radical prostatectomy. Each FCH positive node was assigned to a lymph node station with respect to the CTV defined by the RTOG guidelines (CTV RTOG ). 3D mapping was performed after each node was manu…

MaleFluorine Radioisotopesmedicine.medical_treatment[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineCholineProstate cancerProstatemedicineHumansRadiology Nuclear Medicine and imagingLymph nodeComputingMilieux_MISCELLANEOUSSalvage TherapyPET-CTmedicine.diagnostic_testProstatectomybusiness.industryProstatic NeoplasmsHematologyProstate-Specific Antigenmedicine.diseaseOccult3. Good healthRadiation therapymedicine.anatomical_structureOncologyPositron emission tomographyLymphatic MetastasisPositron-Emission TomographyKallikreinsLymph NodesNeoplasm Recurrence LocalRadiopharmaceuticalsNuclear medicinebusinessTomography X-Ray Computed
researchProduct

Follistatin as potential therapeutic target in prostate cancer

2012

Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins' inhibitory activity. This review provides insight into the most recent advances in understa…

MaleFollistatinendocrine systemCancer Researchmedicine.medical_specialtyanimal structuresGlycosylated proteinProstate cancerInternal medicinemedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyActivin Bone metastasis.Cancer . Follistatin Prostate cancerbiologybusiness.industryProstatic NeoplasmsCancerBone metastasisSUPERFAMILYmedicine.diseaseEndocrinologyOncologyembryonic structuresDisease Progressionbiology.proteinCancer researchbusinesshormones hormone substitutes and hormone antagonistsFunction (biology)FollistatinTransforming growth factor
researchProduct